Regulus Therapeutics Inc. - RGLS Operating profit EBITDA
Regulus Therapeutics (RGLS) relies on partnerships with biotech giants to combat kidney pathologies. The EBITDA volume on this GURU.Markets platform chart demonstrates resilience, where captures the current value of the indicator. Efficiency is confirmed by transparent orphan drug tests, the management's skilled fundraising, and diversified oligonucleotide production via external contractors for the development of miRNA drugs.
Regulus Therapeutics Inc. (RGLS) - metric breakdowns and financial figures
- stock price and consensus target price:
- issuer market value details:
- book value of equity indicators:
- debt level and financial liquidity data:
Aggregate Debt to Capital Regulus Therapeutics|RGLS - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Regulus Therapeutics, Inc.|RGLS - Company Aggregate Debts|Debts to Book Value Regulus Therapeutics|RGLS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Regulus Therapeutics|Quick Ratio regulusrx.com
- company profitability and valuation multiples indicators:
RGLS - Company Net Income|Forward Earnings Regulus Therapeutics|RGLS - P/E Multiple|Projected Price to Earnings Ratio regulusrx.com|RGLS - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Regulus Therapeutics|RGLS - Operating profit before deduction of amortization|Earnings per share for the last four quarters Regulus Therapeutics|RGLS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months regulusrx.com|RGLS - Earnings growth in current year|Expected earnings per share growth for next year Regulus Therapeutics
Summary company analytics:Regulus Therapeutics
An analysis of the EBITDA_Co trend confirms the status of Regulus Therapeutics (RGLS) as a high-tech issuer implementing robotic miRNA screening to accelerate drug development. This metric captures the actual cash flow from core operations, allowing investors to assess the stability of operating margins and the risk of prolonged drawdowns should business model efficiency decline during periods of market cooling.
Competitors of Regulus Therapeutics (RGLS)
Tempus - Profit before payment of interest, taxes and amortization|QGEN: Operating profit before deduction of amortization|IONS - Operating profit EBITDA|Repligen (RGEN) - Profit before payment of interest, taxes and amortization|RNA - Operating income before deduction of amortization|Operating profit before deduction of amortization CRSP|WGS: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization RARE (Ultragenyx Pharmaceutical)|Company profit before taxes, interest and amortization BEAM|Operating profit EBITDA SRPT (Sarepta)|Income before deduction of interest, taxes and amortization TWST|10x Genomics Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Intellia Corp|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|biolifesolutions.com - Income before deduction of interest, taxes and amortization|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Operating profit EBITDA Maze Therapeutics, Inc.|Profit before payment of interest, taxes and amortization Sionna Pharma (SION)|PRME: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA TSHA (Taysha Gene Therapies)|uniqure.com (QURE) - Profit before interest, taxes and amortization|MGTX: Operating profit before deduction of amortization|RGNX - Operating profit EBITDA|SLDB (Solid Bio) - Operating profit before deduction of amortization|OCGN: Company profit before taxes, interest and amortization|PACB (Pacific Biosciences) - Operating profit EBITDA|benitec.com (BNTC) - Operating income before deduction of amortization|Operating profit EBITDA DSGN|Operating profit before deduction of amortization Rocket Pharma RCKT|Profit before payment of interest, taxes and amortization 4D Molecular Therapeutics Inc FDMT|Operating income before deduction of amortization Lexeo Therapeutics Inc. (LXEO)|KRRO - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization EDIT (editasmedicine.com)|SLN: Operating profit EBITDA|Operating profit before depreciation charges ProQR Therapeutics PRQR|Profit before payment of interest, taxes and amortization Codexis Inc|Profit before payment of interest, taxes and amortization SGMO|Profit before payment of interest, taxes and amortization Nautilus Biotechnology (NAUT)|Operating income before deduction of amortization metagenomi.co|Operating profit EBITDA DTIL (Precision BioSciences, Inc.)|GBIO: Operating profit before amortization|BOLD - Profit before payment of interest, taxes and amortization|XCUR (Exicure, Inc.) - Operating profit before amortization|IMNN: Operating profit EBITDA|Phio Pharmaceuticals Corp. (PHIO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Mustang Bio Inc|RNAZ: Income before deduction of interest, taxes and amortization|Operating profit EBITDA BNGO|APDN - Profit before interest, taxes and amortization|Operating profit EBITDA BLUE (bluebird bio, Inc.)|Operating profit before depreciation charges ImmunoPrecise Antibodies Ltd|OMGA: Operating profit before deduction of amortization|OMIC - Operating profit EBITDA|Syros (SYRS) - Profit before payment of interest, taxes and amortization|TBIO (Telesis Bio, Inc) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization TCON|Operating profit EBITDA unitybiotechnology.com
